文献速递慢阻肺肺结节与肺癌

高风险人群肺癌序贯筛查:LungSEARCH随机对照试验

Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group.
PubMed 文献 · Eur Respir J · 2019-10-17

LungSEARCH是一项英国多中心随机对照试验,将1568例轻中度COPD的现吸烟者/既往吸烟者按1:1分配至5年筛查组或对照组。筛查组每年提供痰液进行细胞学/细胞计数,异常者接受年度低剂量CT和自身荧光支气管镜。筛查组早期肺癌比例为54.8%(23/42),对照组为45.2%(14/31),差异无统计学意义(单侧p=0.24)。序贯策略未带来明确的分期偏移,也未提高筛查效率。

要点

  • 痰液细胞学/细胞计数序贯LDCT和AFB筛查未显著提高早期肺癌检出比例。
  • 痰液筛查总体敏感性低(40.5%),累积假阳性率32.8%,55%的癌症痰液结果始终正常。
  • 痰液阳性者中,LDCT敏感性100%、累积假阳性率16.1%,AFB分别为45.5%和39.5%。

核心结论

  • 使用痰液细胞学/细胞计数选择高风险个体进行AFB和LDCT的序贯策略未导致明确的分期偏移,也未提高肺癌筛查效率。

研究设计与样本

  • LungSEARCH为英国10中心国家多中心随机对照试验,2007-2011年随机1568例轻/中度COPD的现吸烟者或既往吸烟者,按1:1分配至5年筛查组或对照组。

主要发现

  • 筛查组785例中诊断42例肺癌,对照组783例中诊断36例肺癌。
  • 筛查组已知分期的患者中早期疾病占54.8%(23/42),对照组为45.2%(14/31),单侧p=0.24。
  • 早期癌症的相对风险为1.21(95%CI 0.75-1.95),晚期癌症的相对风险为0.82(95%CI 0.52-1.31)。
  • 筛查组痰液总体敏感性为40.5%,累积假阳性率为32.8%,55%的癌症痰液结果始终正常。
  • 痰液阳性者中,AFB敏感性45.5%、累积假阳性率39.5%;LDCT敏感性100%、累积假阳性率16.1%。

临床怎么用

  • 对于轻中度COPD的现吸烟者或既往吸烟者,不推荐采用痰液细胞学/细胞计数序贯AFB和LDCT的筛查策略以提高筛查效率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose computed tomography (LDCT) screening detects early-stage lung cancer and reduces mortality. We proposed a sequential approach targeted to a high-risk group as a potentially efficient screening strategy. METHODS: LungSEARCH was a national multicentre randomised trial. Current/ex-smokers with mild/moderate chronic obstructive pulmonary disease (COPD) were allocated (1:1) to have 5 years surveillance or not. Screened participants provided annual sputum samples for cytology and cytometry, and if abnormal were offered annual LDCT and autofluorescence bronchoscopy (AFB). Those with normal sputum provided annual samples. The primary end-point was the percentage of lung cancers diagnosed at stage I/II (nonsmall cell) or limited disease (small cell). RESULTS: 1568 participants were randomised during 2007-2011 from 10 UK centres. 85.2% of those screened provided an adequate baseline sputum sample. There were 42 lung cancers among 785 screened individuals and 36 lung cancers among 783 controls. 54.8% (23 out of 42) of screened individuals versus 45.2% (14 out of 31) of controls with known staging were diagnosed with early-stage disease (one-sided p=0.24). Relative risk was 1.21 (95% CI 0.75-1.95) or 0.82 (95% CI 0.52-1.31) for early-stage or advanced cancers, respectively. Overall sensitivity for sputum (in those randomised to surveillance) was low (40.5%) with a cumulative false-positive rate (FPR) of 32.8%. 55% of cancers had normal sputum results throughout. Among sputum-positive individuals who had AFB, sensitivity was 45.5% and cumulative FPR was 39.5%; the corresponding measures for those who had LDCT were 100% and 16.1%, respectively. CONCLUSIONS: Our sequential strategy, using sputum cytology/cytometry to select high-risk individuals for AFB and LDCT, did not lead to a clear stage shift and did not improve the efficiency of lung cancer screening.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Spiro SG, Shah PL, Rintoul RC, et al. Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group. Eur Respir J. 2019. PMID: 31537697. doi:10.1183/13993003.00581-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。